Anumana, a leading artificial intelligence-based health technology company and a portfolio entity of nference, has joined the Accelerating Medicines Partnership® (AMP®) Heart Failure programme.

This initiative, managed by the Foundation of the National Institutes of Health (FNIH), unites experts from academia, industry, and government to advance research and improve outcomes for heart failure patients.

The AMP Heart Failure initiative, launched in 2022 in collaboration with the National Heart, Lung, and Blood Institute at the NIH, is a multi-year programme focused on understanding heart failure with preserved ejection fraction (HFpEF) – a complex condition in cardiovascular health.

It involves two main components: first, aggregating data from over 30 existing studies to classify HFpEF subtypes; second, creating a newly characterised cohort of HFpEF patients, enhanced with advanced technologies like digital measurements and AI-driven analysis, to refine treatment options and improve patient outcomes.

Through this partnership, Anumana brings its AI expertise, particularly in developing Software as Medical Device (SaMD) tools that detect diseases through electrocardiogram analysis, supporting AMP’s goal to shift heart failure care towards earlier intervention and improved quality of life for patients.

The programme’s expanded data set also allows Anumana to test its ECG-AI algorithms across a larger patient population, enhancing their ability to identify complex heart conditions and customise treatments.

Heart failure affects nearly 6.7 million adults in the United States, remaining one of the leading causes of death and hospitalisation globally. As an AMP Heart Failure partner, Anumana contributes critical analytical tools and plays a key role in developing new data solutions for HFpEF.

Anumana’s ECG-AI™ LEF algorithm, using 12-lead ECG data to identify low ejection fraction (LEF) – a common yet often undiagnosed sign of heart failure – received US FDA clearance in 2023 and is now under review in Europe. The company also has FDA Breakthrough Device Designations for algorithms targeting pulmonary hypertension, cardiac amyloidosis, and hyperkalemia.
 

Source: anumana.ai

Report Abuse